News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
732,530 Results
Type
Article (63465)
Company Profile (444)
Press Release (668619)
Multimedia
Podcasts (127)
Webinars (18)
Section
Business (194735)
Career Advice (3416)
Deals (35199)
Drug Delivery (128)
Drug Development (85299)
Employer Resources (182)
FDA (17452)
Job Trends (15225)
News (343406)
Policy (35850)
Tag
Academia (2950)
Academic (1)
Accelerated approval (12)
Adcomms (32)
Allergies (105)
Alliances (50576)
ALS (118)
Alzheimer's disease (1562)
Antibody-drug conjugate (ADC) (187)
Approvals (17401)
Artificial intelligence (360)
Autoimmune disease (36)
Automation (19)
Bankruptcy (371)
Best Places to Work (11850)
BIOSECURE Act (22)
Biosimilars (135)
Biotechnology (326)
Bladder cancer (100)
Brain cancer (40)
Breast cancer (387)
Cancer (3063)
Cardiovascular disease (246)
Career advice (2894)
Career pathing (33)
CAR-T (209)
CDC (41)
Cell therapy (570)
Cervical cancer (24)
Clinical research (69747)
Collaboration (1100)
Company closure (3)
Compensation (710)
Complete response letters (34)
COVID-19 (2878)
CRISPR (67)
C-suite (353)
Cystic fibrosis (121)
Data (3071)
Decentralized trials (2)
Denatured (39)
Depression (75)
Diabetes (375)
Diagnostics (6645)
Digital health (24)
Diversity (7)
Diversity, equity & inclusion (47)
Drug discovery (164)
Drug pricing (150)
Drug shortages (36)
Duchenne muscular dystrophy (134)
Earnings (76094)
Editorial (48)
Employer branding (22)
Employer resources (159)
Events (118636)
Executive appointments (882)
FDA (19167)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1000)
Gene editing (147)
Generative AI (30)
Gene therapy (436)
GLP-1 (924)
Government (5056)
Grass and pollen (6)
Guidances (178)
Healthcare (19868)
HIV (43)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (184)
Immuno-oncology (11)
Indications (40)
Infectious disease (3072)
Inflammatory bowel disease (164)
Inflation Reduction Act (13)
Influenza (70)
Intellectual property (125)
Interviews (662)
IPO (16696)
IRA (55)
Job creations (3809)
Job search strategy (2365)
Kidney cancer (14)
Labor market (52)
Layoffs (575)
Leadership (25)
Legal (8555)
Liver cancer (85)
Longevity (12)
Lung cancer (429)
Lymphoma (215)
Machine learning (11)
Management (62)
Manufacturing (432)
MASH (98)
Medical device (13904)
Medtech (13907)
Mergers & acquisitions (19250)
Metabolic disorders (956)
Multiple sclerosis (103)
NASH (23)
Neurodegenerative disease (141)
Neuropsychiatric disorders (41)
Neuroscience (2311)
NextGen: Class of 2025 (7042)
Non-profit (4839)
Now hiring (41)
Obesity (495)
Opinion (287)
Ovarian cancer (104)
Pain (121)
Pancreatic cancer (123)
Parkinson's disease (200)
Partnered (21)
Patents (319)
Patient recruitment (173)
Peanut (55)
People (57703)
Pharmaceutical (87)
Pharmacy benefit managers (25)
Phase I (21652)
Phase II (30543)
Phase III (23055)
Pipeline (1691)
Policy (242)
Postmarket research (2893)
Preclinical (9417)
Press Release (69)
Prostate cancer (150)
Psychedelics (46)
Radiopharmaceuticals (277)
Rare diseases (524)
Real estate (6125)
Recruiting (72)
Regulatory (24971)
Reports (46)
Research institute (2623)
Resumes & cover letters (544)
Rett syndrome (10)
RNA editing (10)
RSV (57)
Schizophrenia (98)
Series A (172)
Series B (118)
Service/supplier (13)
Sickle cell disease (67)
Special edition (22)
Spinal muscular atrophy (161)
Sponsored (37)
Startups (3718)
State (2)
Stomach cancer (17)
Supply chain (83)
Tariffs (65)
The Weekly (87)
Vaccines (908)
Venture capital (58)
Weight loss (328)
Women's health (47)
Worklife (20)
Date
Today (99)
Last 7 days (382)
Last 30 days (1944)
Last 365 days (32952)
2025 (17904)
2024 (37012)
2023 (41641)
2022 (52832)
2021 (57445)
2020 (55782)
2019 (48569)
2018 (36862)
2017 (34904)
2016 (34814)
2015 (39967)
2014 (33008)
2013 (27889)
2012 (29738)
2011 (29995)
2010 (28001)
Location
Africa (1022)
Alabama (69)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (43497)
Australia (7554)
California (7627)
Canada (2370)
China (721)
Colorado (329)
Connecticut (342)
Delaware (196)
Europe (100576)
Florida (1146)
Georgia (255)
Hawaii (2)
Idaho (62)
Illinois (690)
India (29)
Indiana (353)
Iowa (18)
Japan (233)
Kansas (111)
Kentucky (32)
Louisiana (16)
Maine (73)
Maryland (1083)
Massachusetts (5871)
Michigan (259)
Minnesota (458)
Mississippi (2)
Missouri (92)
Montana (29)
Nebraska (21)
Nevada (77)
New Hampshire (72)
New Jersey (2162)
New Mexico (31)
New York (2153)
North Carolina (1195)
North Dakota (10)
Northern California (3333)
Ohio (243)
Oklahoma (17)
Oregon (37)
Pennsylvania (1635)
Puerto Rico (17)
Rhode Island (35)
South America (1397)
South Carolina (35)
South Dakota (1)
Southern California (2838)
Tennessee (124)
Texas (1151)
United States (28691)
Utah (227)
Virginia (194)
Washington D.C. (77)
Washington State (668)
West Virginia (4)
Wisconsin (81)
732,530 Results for "the parkinson s institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.
January 30, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Rune Labs and Parkinson’s Foundation Launch First Clinical Program to Correlate Genetic and Digital Biomarkers for Parkinson’s Disease
May 29, 2025
·
6 min read
Press Releases
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease
June 5, 2025
·
3 min read
Press Releases
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
July 9, 2025
·
6 min read
Parkinson’s disease
Roche, Prothena Push Parkinson’s Drug to Phase III Despite Mid-Stage Fail
Analysts at Jefferies give Roche and Prothena’s Phase III study just a 25% to 40% probability of success.
June 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated With GBA Mutations
June 11, 2025
·
3 min read
Parkinson’s disease
Ventyx’s Parkinson’s Pill Shows ‘Promising’ Results in Mid-Stage Study, Paving Path to Other Neuro Diseases
Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including Alzheimer’s.
June 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases
May 20, 2025
·
6 min read
Press Releases
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
June 30, 2025
·
7 min read
Parkinson’s disease
Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial
The report comes just two days after Novartis announced its own Parkinson’s drug failure.
December 19, 2024
·
1 min read
·
Annalee Armstrong
1 of 73,253
Next
